Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
TW-37
Cat No.
CEI-0181
Description
As a new inhibitor,TW-37 can recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 uM, 1.11 uM and 0.26 uM.
CAS No.
877877-35-5
Molecular Weight
573.7
Purity
>99%
Storage
2 years at -20 centigrade
Targets
Bcl-2, Bcl-xL, Mcl-1
Molecular Formula
C33H35NO6S
Chemical Name
5-(2-isopropylbenzyl)-N-(4-(2-tert-butylphenylsulfonyl)phenyl)-2,3,4-trihydroxybenzamide
Solubility
DSMO 115 mg/mL Water
In vitro
As a potent inhibitor of Bcl-2, TW-37 can inhibit recombinant Bcl-2, Bcl-X(L), and Mcl-1 with Ki of 290 nM,110 nM and 260 nM. And TW-37 shows selectivity for Bcl-X(L). For cell lines, TW-37 showed significant antiproliferative effect to WSU-DLCL(2) lymphoma cell line and primary cells. TW-37 disrupted heterodimer formation between Bax and antiapoptotic proteins including Mcl-1, Bcl-2, and Bcl-X(L). TW-37 inhibited cell growth in a dose- and time-dependent manner. This was accompanied by increased apoptosis and concomitant attenuation of NF-kappaB, and downregulation of NF-kappaB downstream genes such as MMP-9 and VEGF, resulting in the inhibition of pancreatic cancer cell migration, invasion and angiogenesis in vitro. And TW-37 can cause apoptotic death.
In vivo
In Colo-357 human PC xenografts in SCID mice, TW-37 treatment signi?cantly inhibited tumor growth. TW-37 could affect the function of NF-kappaB in vivo, and the expression of VEGF, MMP-9, COX-2, Cyclin D1 and Survivin was also downregulated in TW-37-treated animals.
Download
Download Datasheet